Candriam S.C.A. Karyopharm Therapeutics Inc. Transaction History

Candriam S.C.A.

  • $17.1 Billion
  • Q3 2024

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.68 - $1.31 $414,800 - $799,100
-610,000 Reduced 53.48%
530,694 $456,000
Q3 2023

Nov 13, 2023
SELL
$1.14 - $1.81 $336,300 - $533,950
-295,000 Reduced 20.55%
1,140,694 $1.53 Million
Q2 2023

Aug 08, 2023
SELL
$1.79 - $4.59 $177,804 - $455,933
-99,332 Reduced 6.47%
1,435,694 $2.57 Million
Q4 2022

Feb 13, 2023
BUY
$2.48 - $5.93 $496,000 - $1.19 Million
200,000 Added 14.98%
1,535,026 $5.22 Million
Q3 2022

Nov 10, 2022
BUY
$4.08 - $5.82 $405,152 - $577,937
99,302 Added 8.04%
1,335,026 $7.29 Million
Q2 2022

Aug 03, 2022
SELL
$4.15 - $8.37 $412,103 - $831,157
-99,302 Reduced 7.44%
1,235,724 $5.57 Million
Q1 2022

May 13, 2022
BUY
$5.91 - $14.38 $2.7 Million - $6.58 Million
457,358 Added 52.11%
1,335,026 $9.84 Million
Q4 2021

Feb 10, 2022
BUY
$5.21 - $8.61 $833,600 - $1.38 Million
160,000 Added 22.29%
877,668 $5.64 Million
Q2 2021

Jul 20, 2021
SELL
$8.11 - $11.11 $1.9 Million - $2.6 Million
-233,906 Reduced 24.58%
717,668 $7.41 Million
Q1 2021

Apr 29, 2021
SELL
$9.85 - $17.69 $39 - $70
-4 Reduced -0.0%
951,574 $14.1 Million
Q4 2020

Jan 22, 2021
BUY
$14.15 - $17.19 $6.06 Million - $7.36 Million
428,208 Added 81.82%
951,578 $14.7 Million
Q3 2020

Oct 19, 2020
BUY
$14.14 - $19.71 $3.73 Million - $5.2 Million
263,907 Added 101.71%
523,370 $7.64 Million
Q2 2020

Jul 23, 2020
SELL
$16.6 - $25.25 $9.73 Million - $14.8 Million
-585,903 Reduced 69.31%
259,463 $4.91 Million
Q1 2020

May 26, 2020
BUY
$14.38 - $27.72 $460 - $887
32 Added 0.0%
845,366 $15.8 Million
Q4 2019

Jan 21, 2020
SELL
$9.23 - $19.67 $2.09 Million - $4.46 Million
-226,894 Reduced 21.16%
845,334 $16,000
Q3 2019

Oct 21, 2019
SELL
$5.66 - $11.85 $4.95 Million - $10.4 Million
-874,550 Reduced 44.92%
1,072,228 $10,000
Q2 2019

Aug 01, 2019
BUY
$4.32 - $6.43 $345,600 - $514,400
80,000 Added 4.29%
1,946,778 $11.6 Million
Q1 2019

May 02, 2019
BUY
$4.12 - $10.25 $305,844 - $760,898
74,234 Added 4.14%
1,866,778 $10.9 Million
Q4 2018

Feb 14, 2019
BUY
$8.2 - $16.95 $5.8 Million - $12 Million
707,044 Added 65.14%
1,792,544 $16.8 Million
Q3 2018

Nov 07, 2018
BUY
$17.03 - $21.18 $10.1 Million - $12.6 Million
593,500 Added 120.63%
1,085,500 $18.5 Million
Q2 2018

Aug 14, 2018
BUY
$12.0 - $19.88 $3.26 Million - $5.41 Million
272,000 Added 123.64%
492,000 $8.36 Million
Q1 2018

May 09, 2018
SELL
$9.92 - $17.25 $1.82 Million - $3.16 Million
-183,000 Reduced 45.41%
220,000 $2.95 Million
Q4 2017

Feb 07, 2018
SELL
$9.15 - $11.99 $979,050 - $1.28 Million
-107,000 Reduced 20.98%
403,000 $3.87 Million
Q3 2017

Nov 03, 2017
BUY
$8.15 - $11.16 $4.16 Million - $5.69 Million
510,000
510,000 $5.6 Million

Others Institutions Holding KPTI

# of Institutions
98
Shares Held
57.6M
Call Options Held
258K
Put Options Held
81.2K
View Full List

About Karyopharm Therapeutics Inc.

KPTI Quotes by TradingView
  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $51.1M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email